{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:41:27Z","timestamp":1789555287789,"version":"build-2803163510"},"reference-count":54,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T00:00:00Z","timestamp":1453075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Eisai Co. Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neurosci Ther"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Alzheimer's disease (AD) is a progressive condition that affects cognition, function, and behavior. Approximately 60\u201390% of patients with AD develop neuropsychiatric symptoms (NPS) such as hallucinations, delusions, agitation\/aggression, dysphoria\/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep disturbances, appetite and eating changes, or altered sexual behavior. These noncognitive behavior changes are thought to result from anatomical and biochemical changes within the brain, and have been linked, in part, to cholinergic deficiency. Cholinesterase inhibitors may reduce the emergence of NPS and have a role in their treatment. These agents may delay initiation of, or reduce the need for, other drugs such as antipsychotics. This article summarizes the effects of donepezil, a cholinesterase inhibitor, on the NPS of dementia with emphasis on AD and dementia with Lewy bodies.<\/jats:p>","DOI":"10.1111\/cns.12484","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T07:50:45Z","timestamp":1453103445000},"page":"159-166","source":"Crossref","is-referenced-by-count":109,"title":["Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies"],"prefix":"10.1111","volume":"22","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas NV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te\u2010Jen","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Chung Shan Medical University Hospital Institute of Medicine Chung Shan Medical University Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solaphat","family":"Hemrungrojn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry King Chulalongkorn Memorial Hospital Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mohandas","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine Sun Medical and Research Centre Thrissur Kerala India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"Yun Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology Seoul National University College of Medicine &amp; Seoul National University Bundang Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Neurology Fortis Hospital Mahim Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Dash","sequence":"additional","affiliation":[{"name":"Eisai Co. Ltd. Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040223"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80145-8"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903236731"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.181.6.463"},{"key":"e_1_2_10_6_1","first-page":"1","article-title":"Behavioral and psychological symptoms of dementia: Part I\u2014epidemiology, neurobiology, heritability, and evaluation","volume":"19","author":"Tampi RR","year":"2011","journal-title":"Clin Geriatr"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.72"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.5.805"},{"key":"e_1_2_10_9_1","first-page":"404","article-title":"Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type","volume":"10","author":"Pinto T","year":"2011","journal-title":"Ageing Res Rev"},{"issue":"4","key":"e_1_2_10_10_1","first-page":"S1","article-title":"Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease","volume":"11","author":"Cummings JL","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2005.09.016"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.02.010"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000066508"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5_Suppl_6.10S"},{"key":"e_1_2_10_15_1","unstructured":"World Health Organization.Neurological disorders: Public health challenges. Chapter 3: A public health approach. Geneva: World Health Organization; 2006. Available from:www.who.int\/mental_health\/neurology\/neurodiso\/en\/Accessed 22 January 2015."},{"key":"e_1_2_10_16_1","first-page":"9","article-title":"Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment","volume":"48","author":"Reisberg B","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/44.3.M77"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-87"},{"key":"e_1_2_10_20_1","first-page":"2","article-title":"Behavioral and psychological symptoms of dementia: Part II\u2014treatment","volume":"19","author":"Tampi RR","year":"2011","journal-title":"Clin Geriatr"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.5.596"},{"key":"e_1_2_10_22_1","first-page":"487","article-title":"Behavioral and psychological disturbances in Alzheimer disease: Assessment and treatment","volume":"47","author":"Donnelly ML","year":"2005","journal-title":"B C Med J"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200303000-00008"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.08121844"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07111779"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"e_1_2_10_27_1","unstructured":"US Food and Drug Administration.Public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances.2005. Available from:http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm053171Accessed 22 January 2015."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318212ab7a"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519020-00001"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125001029"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200211000-00007"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1388"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000221293.91312.d3"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.12.2.209"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000129990.32253.7B"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.4.613"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1325"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S4250"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-132690"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-122140"},{"key":"e_1_2_10_41_1","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta\u2010analysis","volume":"3","author":"Hansen RA","year":"2008","journal-title":"Clin Interv Aging"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2001.49266.x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68350-5"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051201"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12076"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.3.5.425"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23557"},{"key":"e_1_2_10_48_1","unstructured":"Aricept\u00aeapproved in Japan as treatment for dementia with Lewy bodies. World's first treatment for both Alzheimer's disease and dementia with Lewy bodies. News release: 19 September 2014. Available from:http:\/\/www.eisai.com\/news\/news201452.htmlAccessed 12 May 2015."},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351672"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0083-0"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12089"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12140"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.490"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000036904.73393.E4"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-2"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcns.12484","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cns.12484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:40:06Z","timestamp":1695033606000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cns.12484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,18]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/cns.12484"],"URL":"https:\/\/doi.org\/10.1111\/cns.12484","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,18]]}}}